Analysts Are Bullish on These Healthcare Stocks: Neovasc Inc (NVCN), Pieris Pharmaceuticals (PIRS)


There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Neovasc Inc (NASDAQ:NVCN), Pieris Pharmaceuticals (NASDAQ:PIRS) and Stemline Therapeutics Inc (NASDAQ:STML) with bullish sentiments.

Neovasc Inc (NVCN)

In a report released yesterday, Jason Mills from Canaccord Genuity maintained a Buy rating on Neovasc Inc, with a price target of $0.10. The company’s shares opened today at $0.04, close to its 52-week low of $0.03.

According to TipRanks.com, Mills is a top 25 analyst with an average return of 30.9% and a 74.1% success rate. Mills covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Boston Scientific Corp, and Staar Surgical Company.

The the analyst consensus on Neovasc Inc is currently a Hold rating.

See today’s analyst top recommended stocks >>

Pieris Pharmaceuticals (PIRS)

Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Pieris Pharmaceuticals today. The company’s shares opened today at $5.37.

According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 9.9% and a 41.1% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Nektar Therapeutics, United Therapeutics, and Mirati Therapeutics.

Currently, the analyst consensus on Pieris Pharmaceuticals is a Strong Buy with an average price target of $10, representing an 86.2% upside. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $12 price target.

.

Stemline Therapeutics Inc (STML)

Cowen & Co. analyst Boris Peaker maintained a Buy rating on Stemline Therapeutics Inc today. The company’s shares opened today at $15.

According to TipRanks.com, Peaker is a 5-star analyst with an average return of 13.8% and a 48.6% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Mersana Therapeutics Inc, and Jounce Therapeutics Inc.

Stemline Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $34, implying a 126.7% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $38 price target.

.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts